31 Dec 2025 | 07:00
Total Voting Rights
/**/
RNS Number : 8807M Hutchmed (China) Limited 31 December 2025
Total Voting Rights
Hong Kong, Shanghai & Florham Park, NJ - Wednesday, December 31, 2025: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) hereby notifies the market that as at December 31, 2025, the issued share capital of HUTCHMED consisted of 872,327,620 ordinary shares of US$0.10 each, with each share carrying one right to vote and with no shares held in treasury.
The above figure of 872,327,620 may be used by shareholders as the denominator for the calculations by which they could determine if they are required to notify their interest in, or a change to their interest in, HUTCHMED shares under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
For illustrative purposes only, the 872,327,620 ordinary shares would be equivalent to 872,327,620 depositary interests (each equating to one ordinary share) which are traded on AIM or, if the depositary interests were converted in their entirety, equivalent to 174,465,524 American depositary shares (each equating to five ordinary shares) which are traded on Nasdaq.
About HUTCHMED
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch‑med.com or follow us on LinkedIn.
CONTACTS
Investor Enquiries
+852 2121 8200 / ir@hutch-med.com
Media Enquiries
FTI Consulting -
+44 20 3727 1030 / HUTCHMED@fticonsulting.com
Ben Atwell / Tim Stamper
+44 7771 913 902 (Mobile) / +44 7421 898 348 (Mobile)
Brunswick - Zhou Yi
+852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
Panmure Liberum
Nominated Advisor and Joint Broker
Atholl Tweedie / Emma Earl / Rupert Dearden
+44 20 7886 2500
Cavendish
Joint Broker
Geoff Nash / Nigel Birks
+44 20 7220 0500
Deutsche Numis
Joint Broker
Freddie Barnfield / Jeffrey Wong / Duncan Monteith
+44 20 7260 1000
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END TVRMZMZZNDGGKZM